[Latest] Global Embolic Protection Device Market Size/Share Worth USD 3,562.2 Million by 2033 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
October 28, 2024 22:00 ET
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Embolic Protection Device Market Size, Trends and Insights By Type of Device...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
October 08, 2024 09:00 ET
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
September 26, 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
September 26, 2024 06:00 ET
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
Peptide Therapeutics Market Size is Expected to Reach USD 85.9 billion, Advancing at a CAGR of 9.6% by 2031: Transparency Market Research Inc.
September 04, 2024 09:43 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The global peptide therapeutics market (ペプチド治療薬市場) is estimated to thrive at a CAGR of...
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
August 21, 2024 02:30 ET
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024 02:30 ET
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...